AstraZeneca Appeals NICE Rejection of Tagrisso for First-Line NSCLC Treatment
核心洞察
AstraZeneca will appeal NICE's decision rejecting Tagrisso (osimertinib) for first-line treatment of EGFR (搜索) mutation-positive non-small cell lung cancer due to cost-effectiveness concerns.
NICE acknowledged Tagrisso extends progression-free survival to 18.9 months versus 10.2 months with standard care, but deemed overall survival data too immature for approval.
The rejection coincides with NICE's approval of Pfizer's competing drug Vizimpro (dacomitinib) for the same patient population, intensifying market competition.
AstraZeneca announced it will appeal the National Institute for Health and Care Excellence's (NICE) decision to reject Tagrisso (osimertinib) for first-line treatment of untreated locally-advanced or metastatic epidermal growth factor receptor (EGFR (搜索)) mutation-positive non-small cell lung cancer (NSCLC) in adults. The rejection was based on cost-effectiveness concerns, with NICE determining the drug does not meet eligibility for End of Life (EoL) consideration.
Clinical Evidence and NICE Assessment
NICE acknowledged that Tagrisso extends both progression-free survival (PFS) and overall survival (OS) compared with first-generation EGFR (搜索)-targeting drugs Iressa and Tarceva, but expressed uncertainty about the magnitude of clinical benefit. An interim analysis of AstraZeneca's FLAURA trial demonstrated statistically significant improvement in PFS, with median PFS reaching 18.9 months for osimertinib (95% confidence interval 15.2 to 21.4) compared to 10.2 months for standard care (95% CI 9.6 to 11.1).
However, NICE concluded that overall survival data were very immature, with only 25% of events recorded. The interim results showed Tagrisso extended OS compared with standard care, producing a hazard ratio of 0.63 (95% CI 0.45 to 0.88; p=0.007), which was not statistically significant. Based on this assessment, NICE judged the higher-priced agent not cost-effective since its overall survival performance hasn't yet surpassed older, cheaper alternatives.
End of Life Consideration Dispute
The committee's decision hinged on Tagrisso's failure to meet End of Life criteria, which requires treatment for patients whose life expectancy is normally less than 24 months. AstraZeneca contested this determination, citing real-world data from Public Health England showing overall survival in NHS patients eligible for treatment is less than 17 months, placing it within NICE's range for EoL consideration.
NICE also determined the drug was not eligible for inclusion in the Cancer Drugs Fund, stating it doesn't have the potential to be cost-effective at the offered price.
Competitive Landscape Shift
The Tagrisso rejection coincided with NICE's recommendation of Pfizer's Vizimpro (dacomitinib) for the same patient population, marking a significant competitive development. Clinical results from Pfizer's ARCHER 1050 trial showed patients using Vizimpro achieved longer overall survival rates than those taking AstraZeneca's older EGFR (搜索) targeting drug Iressa, with median patient survival at 34.1 months compared to 26.8 months.
Vizimpro also demonstrated superior progression-free survival compared to gefitinib, extending time before disease progression to 14.7 months versus 9.2 months for Iressa. However, NICE acknowledged Vizimpro's higher incidence of side effects, noting a lower dose may be necessary.
Industry Response and Broader Implications
Pascal Soriot, AstraZeneca's chief executive officer, expressed strong disappointment with the decision, stating: "We are very disappointed with this decision and will appeal. The UK has the second worst lung cancer survival outcomes in Europe and patients need new innovative treatments. Lung cancer patients in England will be deprived of a much needed new treatment option that is already available to patients in many other European countries and around the world."
Soriot called for systemic reform, arguing: "It is time for a comprehensive review of how NICE values innovative medicines. This is needed to ensure British patients can access the latest medical advances, to support the ambitions of the NHS Long Term Plan to improve outcomes for people with cancer, and to help deliver the government's ambition that the UK continues to be a globally leading centre for life sciences."
The CEO emphasized the irony that "Tagrisso, a British discovery, will not be available to patients in England when many countries around the world have already decided to reimburse this medicine." The UK maintains the second worst five-year lung cancer survival rate in Europe, with only Bulgaria showing worse outcomes. Lung cancer represents the leading cause of cancer death in the UK and is the most common cancer type to metastasize to the brain.